Biopharma shake-up: Semnur Pharmaceuticals to merge with Denali Capital in $2.5bn deal

In a significant development within the biopharmaceutical industry, Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali ... Read More